Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy VI: Nursing Management

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Characterizing Gynecological Cancers with the Uncommon dMMR/MSS Phenotype in Lynch Syndrome Patients.

Journal of clinical medicine·2026

Same author

Exercise training for cardiovascular prevention in patients with cancer.

European heart journal·2026

Same author

European Society of Cardiology updated curriculum for heart failure nurses: developed by the Heart Failure Association, in collaboration with the Association of Cardiovascular Nurses and Allied Professions of the European Society of Cardiology.

European journal of heart failure·2026

Same author

Effects of combined high-intensity inspiratory muscle training and aerobic exercise in heart failure: a systematic review and meta-analysis.

European journal of preventive cardiology·2026

Same author

Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors.

European journal of heart failure·2026

Same author

The intermediate-risk gap in AI-based breast cancer stratification.

The Lancet. Oncology·2026

Search research articles

Related Experiment Video

Updated: Sep 16, 2025

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

Cardiotoxicity in Elderly Breast Cancer Patients.

Kalliopi Keramida^1,2, Anastasia Constantinidou^3,4, Dorothea Tsekoura⁵

¹2nd Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Athens University Hospital Attikon, 11527 Athens, Greece.

|July 12, 2025

Summary

Elderly breast cancer patients face significant cardiotoxicity risks from treatments. Comprehensive assessments and tailored strategies are crucial for managing cancer and cardiovascular health in this population.

Keywords:

breast cancer cardiotoxicity elderly frailty heart failure

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Related Experiment Videos

Last Updated: Sep 16, 2025

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Area of Science:

Oncology
Cardiology
Geriatrics

Background:

Cardiotoxicity is a major cause of death in elderly breast cancer (BC) patients.
Treating BC in the elderly is complex due to heterogeneity and underrepresentation in clinical trials.

Purpose of the Study:

To highlight the challenges and necessary considerations for managing breast cancer in elderly patients, focusing on cardiotoxicity.
To emphasize the need for a multidisciplinary approach integrating geriatric assessment and cardiovascular risk evaluation.

Main Methods:

Review of current challenges in elderly breast cancer treatment.
Analysis of factors contributing to cardiotoxicity in this demographic.
Discussion of comprehensive decision-making strategies.

Main Results:

Breast cancer treatments can induce a range of cardiovascular diseases, including heart failure, hypertension, and arrhythmias.
Cardiotoxicity risk is influenced by anticancer therapies, polypharmacy, comorbidities, frailty, and genetic factors.

Conclusions:

A holistic approach is essential, considering BC specifics, patient health, frailty, and cardiotoxicity risk.
Preventive oncological and cardio-oncological strategies, alongside patient education, are vital.
Urgent need for prospective clinical trials focused on elderly breast cancer patients.